| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2022-09-07 11:28:13 UTC |
|---|
| Updated at | 2022-09-07 11:28:13 UTC |
|---|
| NP-MRD ID | NP0249021 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | trifluoperazine |
|---|
| Description | Trifluoperazine, also known as stelazine or triftazin, belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring. As of 2014 there was no good evidence for a difference between trifluoperazine and placebo with respect to the risk of experiencing intensified symptoms over a 16-week period nor in reducing significant agitation or distress. The annual development rate of tardive dyskinesia may be as high as 4%. Brand names include Eskazinyl, Eskazine, Jatroneural, Modalina, Stelazine, Terfluzine, Trifluoperaz, Triftazin. Trifluoperazine is a drug which is used for the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation. Trifluoperazine is a very strong basic compound (based on its pKa). Trifluoperazine is a potentially toxic compound. All antipsychotics can cause the rare and sometimes fatal neuroleptic malignant syndrome. trifluoperazine is found in Crotalaria assamica. trifluoperazine was first documented in 2001 (PMID: 11121417). It is of the phenothiazine chemical class (PMID: 14974020) (PMID: 15722405) (PMID: 19277699). |
|---|
| Structure | CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1 InChI=1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3 |
|---|
| Synonyms | | Value | Source |
|---|
| 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine | ChEBI | | 10-[3-(4-METHYL-piperazin-1-yl)-propyl]-2-trifluoromethyl-10H-phenothiazine | ChEBI | | Trifluoperazina | ChEBI | | Trifluoperazinum | ChEBI | | Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine | ChEBI | | Trifluoroperazine | ChEBI | | Trifluperazine | ChEBI | | Apo-trifluoperazine | Kegg | | Trifluoperazin | HMDB | | Trifluoromethylperazine | HMDB | | Trifluroperizine | HMDB | | Rhone poulenc rorer brand OF trifluoperazine hydrochloride | HMDB | | Rhone-poulenc rorer brand OF trifluoperazine hydrochloride | HMDB | | Trifluoperazine HCL | HMDB | | Allphar brand OF trifluoperazine hydrochloride | HMDB | | Apotex brand OF trifluoperazine hydrochloride | HMDB | | GlaxoSmithKline brand OF trifluoperazine hydrochloride | HMDB | | Link brand OF trifluoperazine hydrochloride | HMDB | | Psicofarma brand OF trifluoperazine hydrochloride | HMDB | | SmithKline beecham brand OF trifluoperazine hydrochloride | HMDB | | Stelazine | HMDB | | Triftazin | HMDB | | Apo trifluoperazine | HMDB | | ApoTrifluoperazine | HMDB | | Eskazine | HMDB | | Flupazine | HMDB | | Scios brand OF trifluoperazine hydrochloride | HMDB | | Terfluzine | HMDB | | Trifluoperazine hydrochloride | HMDB |
|
|---|
| Chemical Formula | C21H24F3N3S |
|---|
| Average Mass | 407.4960 Da |
|---|
| Monoisotopic Mass | 407.16430 Da |
|---|
| IUPAC Name | 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine |
|---|
| Traditional Name | trifluoperazine |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1 |
|---|
| InChI Identifier | InChI=1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3 |
|---|
| InChI Key | ZEWQUBUPAILYHI-UHFFFAOYSA-N |
|---|
| Experimental Spectra |
|---|
|
| Not Available | | Predicted Spectra |
|---|
|
| | Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
|---|
| 1D NMR | 13C NMR Spectrum (1D, 25 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Benzothiazines |
|---|
| Sub Class | Phenothiazines |
|---|
| Direct Parent | Phenothiazines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Phenothiazine
- Alkyldiarylamine
- Diarylthioether
- Aryl thioether
- Tertiary aliphatic/aromatic amine
- N-alkylpiperazine
- N-methylpiperazine
- Para-thiazine
- 1,4-diazinane
- Piperazine
- Benzenoid
- Tertiary aliphatic amine
- Tertiary amine
- Azacycle
- Thioether
- Organic nitrogen compound
- Hydrocarbon derivative
- Organonitrogen compound
- Organofluoride
- Organohalogen compound
- Organopnictogen compound
- Amine
- Alkyl halide
- Alkyl fluoride
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Shin SY, Kim SY, Kim JH, Min DS, Ko J, Kang UG, Kim YS, Kwon TK, Han MY, Kim YH, Lee YH: Induction of early growth response-1 gene expression by calmodulin antagonist trifluoperazine through the activation of Elk-1 in human fibrosarcoma HT1080 cells. J Biol Chem. 2001 Mar 16;276(11):7797-805. doi: 10.1074/jbc.M009465200. Epub 2000 Dec 19. [PubMed:11121417 ]
- Marques LO, Lima MS, Soares BG: Trifluoperazine for schizophrenia. Cochrane Database Syst Rev. 2004;2004(1):CD003545. doi: 10.1002/14651858.CD003545.pub2. [PubMed:14974020 ]
- Choi SY, Koh YS, Jo SH: Inhibition of human ether-a-go-go-related gene K+ channel and IKr of guinea pig cardiomyocytes by antipsychotic drug trifluoperazine. J Pharmacol Exp Ther. 2005 May;313(2):888-95. doi: 10.1124/jpet.104.080853. Epub 2005 Feb 18. [PubMed:15722405 ]
- Qin J, Zima AV, Porta M, Blatter LA, Fill M: Trifluoperazine: a rynodine receptor agonist. Pflugers Arch. 2009 Aug;458(4):643-51. doi: 10.1007/s00424-009-0658-y. Epub 2009 Mar 11. [PubMed:19277699 ]
- LOTUS database [Link]
|
|---|